权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

DEtermining Capacity and Informing Down syndrome Assent Strategies (DECIDAS)

确定能力并告知唐氏综合症同意策略 (DECIDAS)

基本信息

批准号：
10696233
负责人：
Daniel Combs
金额：
$ 23.03万
依托单位：
UNIVERSITY OF ARIZONA
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-08 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10696233
关键词：
6 year old 7 year old Adult Advocacy Age Agreement Authorization documentation Birth Child Childhood Clinic Clinical Assessment Tool Clinical Research Clinical Trials Cognition Collaborations Competence Consent Data Decision Making Down Syndrome Enrollment Ethicists Exclusion Family member Foundations Funding Genetic Goals Hepatitis Hypothyroidism Impaired cognition Individual Informed Consent Intellectual functioning disability Knowledge Legal Legal Guardians Obstructive Sleep Apnea Parents Participant Persons Population Prevalence Process Registries Research Resources Rights Risk Sampling Schools Selection Bias Surveys United States United States National Institutes of Health authority common rule comorbidity congenital heart disorder decision-making capacity design empowerment evidence base improved interest marginalization mental age neglect preference prevent programs recruit research study tool

项目摘要

Down Syndrome (DS) is the most common genetic cause of intellectual disability, with a prevalence of one in 700 births. Clinical trials have attempted to identify DS-specific treatments for intellectual disability as well as for the multiple common DS-associated comorbidities. In clinical research studies, both permission from the participant’s parent (or legal guardian in the case of adults with DS requiring one due to intellectual disability) as well as assent from the participating individual are generally required. Many individuals with DS may not have capacity to make decisions about clinical trial participation, but this has never been investigated. There is an existing knowledge gap as there is a lack of evidence to guide the use of assent for participation in research studies in individuals with DS. Current clinical trials for individuals with DS typically require assent for participation from all participants, which prevents enrollment of individuals unable to provide assent. This may lead to a selection bias for higher functioning individuals with DS. This in turn limits generalizability of results to all individuals with DS, creates a potential ceiling effect for therapies intended to improve cognition and is a barrier to study participation for individuals with DS. The overarching goal of this proposal is to develop an evidence-based framework to guide the approach to assent for individuals with DS to participate in clinical trials. This will be achieved leveraging two existing resources. The first is a survey of a large pool of parents of individuals with DS who are interested in research participation recruited through DS- Connect and the LuMind-IDSC foundation. The second is the use of a validated pediatric tool, the modified MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR), to determine the ability of individuals with DS to make decisions about participation in clinical research. Specific Aims include: Aim 1: To determine parent/representative preferences for assent to participate in clinical trials in individuals with DS. Aim 2: To determine the capacity of individuals with DS to make decisions about clinical trial participation in a clinic-recruited sample of children and adults with DS.

唐氏综合症（DS）是智力残疾最常见的遗传原因，患病率为1 / 4